JPRN-jRCT2080224864已完成1 期
A Phase 1, Open-Label, Single-Dose Pharmacokinetic Study of Lasmiditan in Pediatric Patients with Migraine
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 6age old 至 <= 17age old（—）
- 性别
- All
入选标准
- •Participants must have a history of migraine headaches for more than 6 months
- •-Participants must have a history of 2 to 15 migraine headaches per month in the past 2 months
- •-Participants must weigh between 15 and 55 kilograms (kg)
- •-Participants must not have a migraine headache on the day of lasmiditan administration
排除标准
- •-Participants must not be pregnant or nursing
- •-Participants must not have any acute, serious, or unstable medical condition
- •-Participants must not be actively suicidal or at significant risk for suicide, in the opinion of the investigator
- •-Participants must not be on a medicine that acts in the brain and spinal cord
研究者
相似试验
已完成
1 期
A study to investigate the safety, tolerability and activity of IPP-201101 in healthy volunteersSystemic lupus erythematosus (SLE)Musculoskeletal DiseasesSystemic lupus erythematosusISRCTN16878305ImmuPharma S.A16
进行中（未招募）
不适用
A single dose study of BeneFIX (nonacog alfa, recombinant factor IX) in male Chinese subjects with haemophilia B.EUCTR2015-003027-61-Outside-EU/EEAPfizer Inc.12
进行中（未招募）
1 期
Tedizolid PK/Safety study in children 2-12 yearsTreatment or prophylaxis against Gram-positive infectionsMedDRA version: 20.1 Level: LLT Classification code 10053021 Term: Gram-positive bacterial infection System Organ Class: 100000004862EUCTR2015-004595-29-GBCubist Pharmaceuticals, LLC32
进行中（未招募）
不适用
A Phase 1 Pediatric Study for PK/SafetyEUCTR2015-004595-29-Outside-EU/EEACubist Pharmaceuticals LLC32
Unknown
1 期
Pharmacokinetic, Safety, and Efficacy Studyof SPARCs Paclitaxel Injection Concentrate for Nano-Dispersion (PICN) in subjects with Solid Tumors and With or Without HepaticImpairment.CTRI/2021/10/037602Sun Pharma Advanced Research Company Limited